Dr. Kai Rossen of JiuZhou Pharma Officially Joins the International Advisory Board of Angewandte Chemie
Release time:
2026-02-02
Angewandte Chemie International Edition, published by Wiley-VCH, has announced the appointment of new members to its International Advisory Board (IAB). Dr. Kai Rossen, Head of Innovative Drug CDMO Business in Europe at JiuZhou Pharma, has been invited to join the Board.
The International Advisory Board serves as a mechanism for dialogue between the editorial team and the global chemistry community. Board members provide input on the journal’s development, editorial policies, and scientific scope, and participate in regular discussions to support the journal’s continued publication of research across a broad range of chemistry-related fields.
Angewandte Chemie International Edition, the English edition of the historic German journal Angewandte Chemie (originally founded in 1887), is a comprehensive chemistry journal with a long-standing academic tradition and international influence, and is indexed in the Nature Index.
Profile of Dr. Kai Rossen
During his career, Dr. Rossen has held positions at several pharmaceutical and chemical companies, including Merck & Co. (USA), Evonik, Sanofi, Lundbeck (Denmark), and EUROAPI. He has contributed to process research and development supporting the industrialization of multiple pharmaceutical products, including Crixivan, Arcoxia, Aprepitant, and Firocoxib, as well as the catalyst Phanephos, and to the development and scale-up of a new synthetic route for Fexofenadine.
From 2014 to 2025, Dr. Kai Rossen served as Editor-in-Chief of Organic Process Research & Development (OPR&D), a journal published by the American Chemical Society.
At JiuZhou Pharma, Dr. Rossen is responsible for the development and application of strategic research projects, fostering technical exchanges with potential partners, and leading the team to strengthen the company’s core capabilities in green pharmaceutical manufacturing.
Other News
Business Collaboration
Innovative Drug CDMO Services
Tel: 86-576-85588039 / 86-576-85580090
E-mail: bd@jiuzhoupharma.com
Business Collaboration
Innovative Drug CDMO Services
Tel: 86-576-85588039 / 86-576-85580090
E-mail: bd@jiuzhoupharma.com
Established Business Services（API）
Tel: 86-576-88881561
E-mail: bd@jiuzhoupharma.com
